What's in Sri Edupuganti, MD MPH's pipeline?

Sri Edupuganti, MD MPH has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Sri Edupuganti, MD MPH's portfolio?

Top competitors by shared drug class: Bandim Health Project, Beijing Center for Disease Control and Prevention, Bharat Biotech International Limited, Canadian Immunization Research Network, Center for Research and Production of Vaccines and Biologicals, Vietnam.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sri-edupuganti-md-mph.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Sri Edupuganti, MD MPH — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sri Edupuganti, MD MPH pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
MMR vaccine	MMR vaccine	marketed	Live attenuated vaccine		Immunology / Infectious Disease

Therapeutic area mix

Immunology / Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Bandim Health Project · 1 shared drug class
Beijing Center for Disease Control and Prevention · 1 shared drug class
Bharat Biotech International Limited · 1 shared drug class
Canadian Immunization Research Network · 1 shared drug class
Center for Research and Production of Vaccines and Biologicals, Vietnam · 1 shared drug class
Centers for Disease Control and Prevention · 1 shared drug class
Changchun BCHT Biotechnology Co. · 1 shared drug class
Aga Khan University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Sri Edupuganti, MD MPH:

Cite this brief

Drug Landscape (2026). Sri Edupuganti, MD MPH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sri-edupuganti-md-mph. Accessed 2026-05-16.